BeiGene Ltd.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 2010-01-01

Employees: 10K

Market Cap: $22.1B

Website: http://www.beigene.com

Clinical Trials

Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-BGB-3111 in Healthy Males

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: [14C]-BGB-3111
Drug: BGB-3111

First Posted Date: 2019-11-15

Last Posted Date: 2019-11-15

Lead Sponsor: BeiGene

Target Recruit Count: 6

Registration Number: NCT04163783

Locations: 🇺🇸
Covance Clinical Research Unit, Inc.,, Madison, Wisconsin, United States

Study to Evaluate the Effect of Food on the Pharmacokinetics of a BGB-3111 in Healthy Subjects

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Zanubrutinib

First Posted Date: 2019-11-14

Last Posted Date: 2019-11-14

Lead Sponsor: BeiGene

Target Recruit Count: 18

Registration Number: NCT04163523

Locations: 🇦🇺
CMAX, Adelaide, South Australia, Australia

Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment

Phase 2

Recruiting

Conditions: Marginal Zone Lymphoma
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Mantle Cell Lymphoma
Waldenstrom Macroglobulinemia

Interventions: Drug: Zanubrutinib

First Posted Date: 2019-10-04

Last Posted Date: 2024-12-13

Lead Sponsor: BeiGene

Target Recruit Count: 90

Registration Number: NCT04116437

Locations: 🇺🇸
Cci Clearview Cancer Insitute, Huntsville, Alabama, United States
🇺🇸
Arizona Oncology Associates, Pc Hope, Tucson, Arizona, United States
🇺🇸
Innovative Clinical Research Institute, Whittier, California, United States

and more 31 locations

Study Investigating Safety, Tolerability, Pharmacokinetics (PK) and Antitumor Activities of Anti-PD-1 (Programmed Death-1) Monoclonal Antibody

Phase 1

Completed

Conditions: Advanced Solid Tumors

Interventions: Drug: Tislelizumab

First Posted Date: 2019-08-28

Last Posted Date: 2024-10-26

Lead Sponsor: BeiGene

Target Recruit Count: 300

Registration Number: NCT04068519

Locations: 🇨🇳
Sun Yat Sen Memorial Hospital, Sun Yat Sen University (North), Guangzhou, Guangdong, China
🇨🇳
Guangdong Provincial Peoples Hospital, Guangzhou, Guangdong, China
🇨🇳
The Fifth Affiliated Hospital Sun Yat Sen University, Zhuhai, Guangdong, China

and more 9 locations

A Single-Arm, Expanded Access Study of Zanubrutinib in Participants With B-cell Malignancies

Conditions: Waldenström Macroglobulinemia

First Posted Date: 2019-08-12

Last Posted Date: 2024-10-23

Lead Sponsor: BeiGene

Registration Number: NCT04052854

Locations: 🇺🇸
Eisenhower Desert Cardiology Center, Rancho Mirage, California, United States
🇺🇸
Sansum Clinic and Ridley Tree Cancer Center, Santa Barbara, California, United States
🇺🇸
Maryland Oncology Hematology, Pa, Columbia, Maryland, United States

and more 7 locations

Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors

Phase 1

Completed

Conditions: Locally Advanced and Metastatic Solid Tumors

Interventions: Drug: Ociperlimab
Drug: Tislelizumab
Drug: Paclitaxel
Drug: Pemetrexed
Drug: Nab paclitaxel
Drug: Carboplatin
Drug: Cisplatin
Drug: Etoposide
Drug: 5fluorouracil
Drug: Oxaliplatin
Drug: Capecitabine

First Posted Date: 2019-08-07

Last Posted Date: 2024-11-29

Lead Sponsor: BeiGene

Target Recruit Count: 449

Registration Number: NCT04047862

Locations: 🇺🇸
University of Kansas Medical Center Research Institute, Kansas City, Kansas, United States
🇦🇺
St Vincents Hospital, Fitzroy, Victoria, Australia
🇨🇳
Beijing Tongren Hospital, Cmu, Beijing, Beijing, China

and more 26 locations

Study of Platinum Plus Etoposide With or Without BGB-A317 in Participants With Untreated Extensive-Stage Small Cell Lung Cancer

Phase 3

Completed

Conditions: Small Cell Lung Cancer

Interventions: Drug: Tislelizumab, Carboplatin /Cisplatin, Etoposide
Drug: Carboplatin / Cisplatin, Etoposide

First Posted Date: 2019-07-02

Last Posted Date: 2024-05-24

Lead Sponsor: BeiGene

Target Recruit Count: 457

Registration Number: NCT04005716

Locations: 🇨🇳
General Hospital of Nanjing Military Command, Nanjing, Jiangsu, China
🇨🇳
Affiliated Tumor Hospital of Xinjiang Medical University, Ürümqi, Xinjiang, China
🇨🇳
The Second Hospital of Anhui Medical University, Hefei, Anhui, China

and more 47 locations

Study of Tislelizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer

Phase 2

Completed

Conditions: Locally Advanced or Metastatic Urothelial Bladder Cancer

Interventions: Drug: Tislelizumab

First Posted Date: 2019-07-01

Last Posted Date: 2024-10-26

Lead Sponsor: BeiGene

Target Recruit Count: 113

Registration Number: NCT04004221

Locations: 🇨🇳
Fudan University Hua Dong Hospital, Shanghai, Shanghai, China
🇨🇳
Xiangya Hospital central South University, Changsha, Hunan, China
🇨🇳
The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China

and more 27 locations

Study Comparing Zanubrutinib + Rituximab Versus Bendamustine + Rituximab in Participants With Untreated Mantle Cell Lymphoma

Phase 3

Active, not recruiting

Conditions: Mantle Cell Lymphoma; Non-Hodgkin Lymphoma

Interventions: Drug: bendamustine
Drug: zanubrutinib
Drug: rituximab

First Posted Date: 2019-06-28

Last Posted Date: 2024-12-06

Lead Sponsor: BeiGene

Target Recruit Count: 510

Registration Number: NCT04002297

Locations: 🇺🇸
West Penn Hospital, Pittsburgh, Pennsylvania, United States
🇨🇳
Beijing Friendship Hospital, Capital Medical University, Beijing, Beijing, China
🇨🇳
Fujian Medical University Union Hospital, Fuzhou, Fujian, China

and more 173 locations

Study to Investigate the Effect of Rifampin and Itraconazole on the Action of Pamiparib in Participants With Cancer

Phase 1

Completed

Conditions: Solid Tumor

Interventions: Drug: pamiparib 60 mg
Drug: pamiparib 20 mg
Drug: pamiparib
Drug: rifampin
Drug: itraconazole

First Posted Date: 2019-06-21

Last Posted Date: 2024-10-26

Lead Sponsor: BeiGene

Target Recruit Count: 25

Registration Number: NCT03994211

Locations: 🇬🇪
Arensia Exploratory Medicine Llc, Tbilisi, Georgia
🇵🇱
Szpital Luxmed, Warszawa, Poland
🇸🇰
Summit Clinical Research, Sro, Bratislava, Slovakia

and more 1 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy